• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Immunol . Comparative analysis of cellular immune responses to four seasonal inactivated influenza vaccines in younger and older adults

tetano

Editor, Senior Moderator
J Immunol


. 2025 Oct 30:vkaf286.
doi: 10.1093/jimmun/vkaf286. Online ahead of print. Comparative analysis of cellular immune responses to four seasonal inactivated influenza vaccines in younger and older adults

Vanessa Silva-Moraes[SUP] 1 [/SUP], Laise Rodrigues Reis[SUP] 1 [/SUP], Ted M Ross[SUP] 1 2 3 4 [/SUP]



Affiliations
Abstract

The efficacy of seasonal influenza vaccines varies across age groups, even in individuals with strong antibody responses. Since protection against influenza virus infection also involves cellular immunity, identifying immune markers beyond neutralizing antibodies is crucial for informing the design of next-generation vaccines. Participants were categorized by age, 28-60 and 65-85 yr, and were vaccinated with 1 of 4 influenza vaccines (Fluzone Standard-Dose [FSD], Flucelvax [FCEL], Fluzone High-Dose [FHD], or Fluad [FAD]) during the 2023-2024 influenza season. Blood samples were collected before and after vaccination and analyzed for hemagglutination inhibition (HAI) activity, antibody-secreting cells (ASCs), and HA-specific compartments: memory B cells (MBCs), circulating T follicular helper (cTfh) cells, and CD4+ T effector cells. Although all vaccines increased HAI titers, FHD, which contains 4 times more antigen content than the other vaccines, elicited superior cellular responses compared to FAD in older participants. FCEL, produced in mammalian cells, was more effective than the egg-produced FSD in younger adults. Notably, FHD triggered simultaneous ASC and cTfh1 activation in older adults, which were linked to HA-specific MBCs and long-term humoral responses. FCEL induced early and cytokine-secreting HA-specific CD4+ T cell responses in younger adults, correlating with early B cell proliferation and enhanced antibody production. These findings highlight the critical role of antigen dose and quality in inducing HA-specific cellular immunity and coordinating B and T cell activation. Synergistically engaging ASCs, cTfh, MBCs, and CD4+ T cells to enhance immunological memory and establish long-term vaccine-induced immunity should be considered in future influenza vaccine design.

Keywords: B cells; T cells; influenza; vaccination.

 
Back
Top Bottom